Skip to content

Study · Not a test of the peptide alone · 2005

8 results

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.

Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research18 Jan 2005Cited by 216 (Europe PMC)

PMID15883636 (opens in a new tab)DOI10.1359/jbmr.050105 (opens in a new tab)PepBankPUB-15883636
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, PINP increases at 3 months correlated with lumbar spine BMD increases at 18 months.

    In plain wordsIn women in a teriparatide trial, early PINP increases were linked to later spine bone density increases.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP association with lumbar spine BMD
    Study

    n = 771

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Correlation
    0.61 r
    PINP at 3 months and LS BMD at 18 months

    Source sentences

    Summary
    Among all studied biochemical markers, increases in PICP at 1 month and PINP at 3 months correlated best with increases in LS BMD at 18 months (0.65 and 0.61, respectively; p < 0.05).
    2 context sentences
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, PINP relationships with lumbar spine BMD response were stronger than relationships with femoral neck response.

    In plain wordsIn women in a teriparatide trial, PINP had stronger links to spine bone density response than femoral neck response.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePINP association strength by skeletal site
    Study

    n = 771

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The relationships between these two biochemical markers and the LS BMD response were stronger than the corresponding relationships for the femoral neck BMD response.
    3 context sentences
    Summary · context
    Among all studied biochemical markers, increases in PICP at 1 month and PINP at 3 months correlated best with increases in LS BMD at 18 months (0.65 and 0.61, respectively; p < 0.05).
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, early PINP increases were among the most sensitive and accurate predictors of lumbar spine BMD response.

    In plain wordsIn women in a teriparatide trial, early PINP increases were among the best predictors of spine bone density response.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePINP prediction of lumbar spine BMD response
    Study

    n = 771

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Using receiver operator curve analysis, we determined that the increases in PICP at 1 month and PINP at 3 months were the most sensitive and accurate predictors of the LS BMD response.
    2 context sentences
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, PICP increases at 1 month correlated with lumbar spine BMD increases at 18 months.

    In plain wordsIn women in a teriparatide trial, early PICP increases were linked to later spine bone density increases.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePICP association with lumbar spine BMD
    Study

    n = 520

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Correlation
    0.65 r
    PICP at 1 month and LS BMD at 18 months

    Source sentences

    Summary
    Among all studied biochemical markers, increases in PICP at 1 month and PINP at 3 months correlated best with increases in LS BMD at 18 months (0.65 and 0.61, respectively; p < 0.05).
    2 context sentences
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, PICP relationships with lumbar spine BMD response were stronger than relationships with femoral neck response.

    In plain wordsIn women in a teriparatide trial, PICP had stronger links to spine bone density response than femoral neck response.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePICP association strength by skeletal site
    Study

    n = 520

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The relationships between these two biochemical markers and the LS BMD response were stronger than the corresponding relationships for the femoral neck BMD response.
    3 context sentences
    Summary · context
    Among all studied biochemical markers, increases in PICP at 1 month and PINP at 3 months correlated best with increases in LS BMD at 18 months (0.65 and 0.61, respectively; p < 0.05).
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, early PICP increases were among the most sensitive and accurate predictors of lumbar spine BMD response.

    In plain wordsIn women in a teriparatide trial, early PICP increases were among the best predictors of spine bone density response.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePICP prediction of lumbar spine BMD response
    Study

    n = 520

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Using receiver operator curve analysis, we determined that the increases in PICP at 1 month and PINP at 3 months were the most sensitive and accurate predictors of the LS BMD response.
    2 context sentences
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, baseline bone turnover correlated positively and significantly with BMD response.

    In plain wordsIn women in a teriparatide trial, higher baseline bone turnover was linked to greater bone density response.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBaseline bone turnover association with BMD response
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Baseline bone turnover status correlated positively and significantly with BMD response.
    2 context sentences
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  8. 08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women in a teriparatide trial, the highest correlations concerned lumbar spine BMD response to teriparatide 20 microg/day.

    In plain wordsIn women in a teriparatide trial, the strongest correlations concerned spine bone density response to the lower dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableStrongest BMD-response correlations
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The highest correlations occurred for the LS BMD response to teriparatide 20 microg/day.
    2 context sentences
    Summary · context
    The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied.
    Summary · context
    In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 microg/day, or teriparatide 40 microg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.